myelin-basic-protein and Behcet-Syndrome

Neuro-Behçet's disease (NBD) contributes to poor prognosis in BD patients which lacks reliable laboratory biomarkers in assessing intrathecal injury. This study aimed to determine the diagnostic value of myelin basic protein (MBP), an indicator of central nervous system (CNS) myelin damage, in NBD patients and disease controls. Paired samples of cerebrospinal fluid (CSF) and serum MBP were measured using ELISA, while IgG and Alb were routinely examined before the MBP index was developed. CSF and serum MBP in NBD were significantly higher than in NIND, which could distinguish NBD from NIND with a specificity exceeding 90%, moreover, they could also be excellent discriminators for acute NBD and chronic progressive ones. We found positive linkage between MBP index and IgG index. Serial MBP monitoring confirmed serum MBP's sensitive response to disease recurrences and drug effects, whereas MBP index suggests relapses prior to clinical symptoms. MBP has high diagnostic yield for NBD with demyelination and identifies CNS pathogenic processes before imaging or clinical diagnosis.

Topics: Behcet Syndrome; Biomarkers; Central Nervous System; Humans; Immunoglobulin G; Myelin Basic Protein

Topics: Autoantibodies; Behcet Syndrome; Diagnosis, Differential; Humans; Multiple Sclerosis; Myelin Basic Protein; Parkinson Disease; Radioimmunoassay

Topics: Behcet Syndrome; Myelin Basic Protein; Radioimmunoassay